Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries
Open accessThe DOI matches its Crossref record; 24 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Several combinations of 2 or 3 direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naive patients. DAAs for HCV infection have similar mechanisms of action and chemical structures to antiretrovirals for human immunodeficiency virus (HIV) infection. Generic antiretrovirals are currently manufactured at very low prices, to treat 10 million people with HIV/AIDS in developing countries. METHODS: Four HCV DAAs, currently either in phase 3 development or recent approval (daclatasvir, sofosbuvir, simeprevir, faldaprevir), and ribavirin were classified by chemical structure, molecular weight, total daily dose, and complexity of synthesis. The likely range of manufacturing costs per gram of DAA were then projected as formulated product cost, based upon treating a minimum of 1 million patients annually (to arrive at volume demand) combined with an analysis of the complexity of synthesis and a 40% margin for formulation. Projections were then compared with actual costs of antiretrovirals with similar structures. RESULTS: Minimum manufacturing costs of antiretrovirals were US$0.2-$2.1 per gram. The complexity of chemical synthesis for HCV DAAs was ranked from lowest to highest: ribavirin, daclatasvir, sofosbuvir, faldaprevir, and simeprevir. Predicted manufacturing costs (US dollars) for 12-week courses of HCV DAAs were $21-$63 for ribavirin, $10-$30 for daclatasvir, $68-$136 for sofosbuvir, $100-$210 for faldaprevir, and $130-$270 for simeprevir. CONCLUSIONS: Within the next 15 years, large-scale manufacture of 2 or 3 drug combinations of HCV DAAs is feasible, with minimum target prices of $100-$250 per 12-week treatment course. These low prices could make widespread access to HCV treatment in low- and middle-income countries a realistic goal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our methodology for calculating drug EMPs has previously accurately predicted how low medication prices can go when they are produced generically [31]; however, this methodology is based on multiple assumptions.”
From Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment (2023) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with cost-based pricing research similar to this, alongside advocacy groups and political will, treatment courses were brought down to <$100 per 12-week treatment course [31,40].”
From Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment (2023) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“when direct-acting antivirals were developed for hepatitis C 10 years ago, courses were $84,000 per person ($1000/pill)”
From Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment (2023) · cites this paper as [31]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Mohd Hanafiah, K., Groeger, J., Flaxman, A. D., & Wiersma, S. T. (2013) · Hepatology · doi:10.1002/hep.26141 · Cited by 2,515 · cited 1×
“Worldwide, 160–180 million people are antibody positive for Hepatitis C, with up to 500 000 HCV-related deaths per year [1, 2].”
BackgroundEvolving epidemiology of hepatitis C virus
Lavanchy, D. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03432.x · Cited by 1,318 · cited 1×
“Sources: Lavanchy [8]; Negro and Alberti [9].”
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Jacobson, I. M., Gordon, S. C., Kowdley, K. V., Yoshida, E. M., Rodriguez-Torres, M., Sulkowski, M. S., Shiffman, M. L., Lawitz, E., Everson, G., Bennett, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214854 · Cited by 1,090 · cited 2×
“Sofosbuvir + RBV POSITRON [15] (n = 207 + 71 placebo) IFN-ineligible 2 12 wk (n = 109) 93% (SVR-12)”
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Gao, M., Nettles, R. E., Belema, M., Snyder, L. B., Nguyen, V. N., Fridell, R. A., Serrano-Wu, M. H., Langley, D. R., Sun, J.-H., O’Boyle II, D. R., et al. (2010) · Nature · doi:10.1038/nature08960 · Cited by 939 · cited 1×
“Daclatasvir has a straightforward synthesis with the cost-limiting intermediate being the substituted biphenyl compound shown (Table 5) [21, 22].”
BackgroundThe WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings
Gilks, C. F., Crowley, S., Ekpini, R., Gove, S., Perriens, J., Souteyrand, Y., Sutherland, D., Vitoria, M., Guerma, T., & De Cock, K. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69158-7 · Cited by 689 · cited 1×
“proaches using tolerable, easy-to-administer regimens that are supportive of task shifting (care delivery by lesser trained health staff ) and good patient adherence, and could be facilitated by widespread access to oral, short-course DAA therapy in lowincome countries [29].”
BackgroundWitkowski, J. T., Robins, R. K., Sidwell, R. W., & Simon, L. N. (1972) · Journal of Medicinal Chemistry · doi:10.1021/jm00281a014 · Cited by 471 · cited 1×
“Analysis revealed that ribavirin has a relatively simple chemical synthesis [20].”
BackgroundLow-cost tools for diagnosing and monitoring HIV infection in low-resource settings
Wu, G., & Zaman, M. H. (2012) · Bulletin of the World Health Organization · doi:10.2471/blt.12.102780 · Cited by 190
The global health burden of hepatitis C virus infection
Negro, F., & Alberti, A. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02537.x · Cited by 181 · cited 1×
“Sources: Lavanchy [8]; Negro and Alberti [9].”
Moon, S., Jambert, E., Childs, M., & von Schoen-Angerer, T. (2011) · Globalization and Health · doi:10.1186/1744-8603-7-39 · Cited by 138
Research works printed but not linked: 5
- 2013, Journal of hepatology, 58, S22
- 2012, Clinical Infectious Diseases, 54, 145
- 2012, Hepatology (Baltimore, Md.), 56, 230A
- 2012, Hepatology (Baltimore, Md.), 56, 306A
- 2012, Hepatology (Baltimore, Md.), 56, 308A
Cited by
Items 201–242 of 242
Thomas, X. V. (2015) · UvA-DARE (University of Amsterdam) · Cited by 1
Overtreating Versus Undertreating: what is the Optimized Treatment Duration in HCV?
Adebajo, C. O., & Reau, N. S. (2015) · Future Virology · doi:10.2217/fvl.15.71
Hepatitis C treatment gets into a new gear.
Khokhar, N. (2014) · PubMed
Políticas públicas y acceso a medicamentos en el Ecuador
Páez, A., & David, F. (2016) · Americanae (AECID Library)
Does Cardiovascular Disease Screening Save Lives in Asymptomatic Adults?
Doval, H. C. (2016) · Revista Argentina de Cardiología · doi:10.7775/rac.es.v84.i4.9213
Carta al Ministro de Salud a propósito de la Guía de manejo de Hepatitis C
Regino, W. O., & Parra, G. A. (2017) · Revista Colombiana de Gastroenterología · doi:10.22516/25007440.149
“Por todo lo anterior, en Colombia, es urgente una racionalización de los pre-cios de los medicamentos contra la hepatitis C con los recursos legales existentes o inventando otros, como las licencias obligatorias para garantizar que la cura de la infección por VHC llegue a todas las personas infectadas bajo la iniciati…”
BackgroundInfluentialRare codons effect on expression of recombinant gene cassette in Escherichia coli BL21(DE3)
Esmaeili‐bandboni, A., Honari, H., & Safaei, S. (2017) · Asian Pacific Journal of Tropical Disease · doi:10.12980/apjtd.7.2017d6-404
“Synergic effects of oral drug (or vaccine) and utilization of the chimeric recombinant proteins that possess a part of drugs (or vaccines) can lessen final cost and used dose of drugs[1,2].”
BackgroundThe Curative HCV Treatments in China
Fei, Y., & Jiang, J. (2018) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2018.68004
“The estimated costs for a 12-week course of DCV treatment were $10 - $30 [68] (Hill et al., 2014).”
BackgroundMethodInfluentialSugimoto, A. (2018) · LSHTM Research Online (London School of Hygiene and Tropical Medicine) · doi:10.17037/pubs.04649770
“With respect to the case of HCV-DAAs, a study has claimed that the high costs of HCV-DAAs were result of the 11 billion USD acquisition of Pharmasset Inc. by Gilead [77] .”
BackgroundInfluentialBarriers to accessibility to antiviral treatment for patients with Chronic Viral HepatitisC in Egypt
Serag, H. (2014) · University of the Western Cape Electronic Theses and Dissertations Repository (University of the Western Cape)
Bellin, A., Franchin, G., Bolcato, J., Bettiol, A., Pirolo, R., Schiavon, A., Giusti, P., Tessarin, M., & Chinellato, A. (2019) · Global & Regional Health Technology Assessment · doi:10.33393/grhta.2019.466
Synthesis of asymmetric phosphonate prodrugs
Foust, B. J., Quinn, D. M., Wiemer, A. J., Wiemer, D. F., Gloer, J. B., & Forbes, T. Z. (2019) · doi:10.17077/etd.hlxo-qg24
“While these prodrugs lose stereochemistry upon hydrolysis of either ester, instances of a difference in bioactivity based on the phosphorus stereochemistry have been published, such as the previously discussed example of Sofosbuvir.66 The difference in measured biological activity could result from the enzymes that ar…”
BackgroundInfluentialChanging Treatment Landscape of Hepatitis C Virus Infection Among Penitentiary Inmates.
Yeo, Y., Johnson, R., & Heng, C. (2016) · Europe PMC (PubMed Central)
Hepatitis C Infection in Dutch HIV-Positive Patients in the Era of Direct-Acting Antiviral Therapy
Boerekamps, A. (2019) · EUR Research Repository (Erasmus University Rotterdam)
Potential Use of Sofosbuvir in the Prophylaxis for Rabies
Reznik, S. E., Tiwari, A. K., & Ashby, C. R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00472
Globale Gesundheitssicherung, nur wie? Kontroversen eines Politikfelds
Hanrieder, T. (2021) · RePEc: Research Papers in Economics
Vakıf medeniyetimizde Darüşşifalar
Akman, A. (2020) · Ibn Haldun University Institutional Repository (Yes)
Çalışkan, Y., Gümrükçüoğlu, Y. B., Erol, Ö. F., Dülger, A., Yakacak, G. A., & Kafalı, Ö. F. (2020) · Ibn Haldun University Institutional Repository (Yes)
Iduh, M. U., Kuta, F. A., Abalaka, M. E., & Shitu, K. O. (2019) · Journal of BioMedical Research and Clinical Practice · doi:10.46912/jbrcp2i1.2019100
Quigley, F. (2018) · Cornell University Press eBooks · doi:10.1515/9781501713910-026
Real-World Therapeutic Outcomes of Direct-Acting Antiviral Regimens and Formidable Challenges
Shahid, I., & Jabeen, Q. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815123432123010012
Direct-acting Antivirals for Hepatitis C and Implication for Community Pharmacy Practice
McEntee, S., Liu, Y., Mahmoudi, T. M., Oliver, K., & Cadwell, C. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230816145931
Kondratiuk, S. V. (2023) · Medicne pravo · doi:10.25040/medicallaw2023.02.023
Application of high throughput sequencing in studies of hepatitis C infection
Rodrigo, P. C. (2017) · UNSWorks (University of New South Wales, Sydney, Australia) · doi:10.26190/unsworks/3188
ID9606/2a-c: Dispositive eines Virus
Vanecek, J. (2022) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.6832450
Prouté, M., Cœur, S. L., Tiv, M. H., Timothee, D., Jongpaijitsakul, P., Ratnamhin, A., Angkurawaranon, C., Aramrattana, A., & Lallemant, M. J. (2020) · Figshare · doi:10.6084/m9.figshare.13004054
Tenni, B. F., Lexchin, J., Akaleephan, C., Kittitrakul, C., & Gleeson, D. (2024) · Figshare · doi:10.6084/m9.figshare.26733247
Iversen, J. (2014) · UNSWorks (University of New South Wales, Sydney, Australia) · doi:10.26190/unsworks/16978
Serag, H. (2014) · University of the Western Cape Electronic Theses and Dissertations Repository (University of the Western Cape)
Costa, L. S. D. (2020) · OhioLink ETD Center (Ohio Library and Information Network)
Politiche di prezzo, rimborso e accesso ai farmaci in Italia \ned Europa: un'analisi comparativa
Staniscia, C. (2020) · Padua@thesis (Department of Information Engineering University of Padova)
Habib, E. (2025) · theses.fr (ABES) · doi:10.71781/2114
Baharuddin, S. (., Dewi, S. M. (., Rahayyu, A. M. (., Yulia, N. (., Yulianti, E. (., Buih, P. H. (., Kustiawan, P. M. (., Sari, M. I. (., Yusuf, M. F. (. )., Ardiani, R. (., et al. (2025) · Neliti
Atmospheres of the Undead: living with viruses, loneliness, and neoliberalism
Berrigan, C. (2026) · Handbooks in philosophy · doi:10.1007/978-3-031-75780-8_31-1
¿El screening de enfermedad cardiovascular salva vidas en adultos asintomáticos?
Doval, H. C. (2026) · Revista Argentina de Cardiología · doi:10.7775/rac.v84i4.4039
Recent Advances in Liver Diseases and Surgery
Abdeldayem, A. E.-S. H., & Salman, T. (2015)
Health economics: a global review and prospection
DAMIAN, T.-G. (2026) · Cognitive Sustainability · doi:10.55343/cogsust.24023
Gao, L., & Li, S. (2026) · Value in Health Regional Issues · doi:10.1016/j.vhri.2026.102132
Metadata
- Authors
- Hill, A., Khoo, S., Fortunak, J., Simmons, B., & Ford, N.
- Affiliations
- University of Liverpool (GB)
- Howard University (US)
- Imperial College London (GB)
- University of Cape Town (ZA)
- Corresponding author
- Hill, A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-06
- Volume
- 58
- Issue
- 7
- Pages
- 928-936
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC3952605
- OpenAlex
- W2163848297
- Semantic Scholar
- 777a83aedceb6c84d3ff7d4176d38d6c2613d4a5
- Cited by
- 216
- References
- 28
- Citations by year
- 2026: 5 · 2025: 1 · 2024: 8 · 2023: 10 · 2022: 9 · 2021: 5 · 2020: 15 · 2019: 14 · 2018: 22 · 2017: 26 · 2016: 34 · 2015: 43 · 2014: 24
- FWCI
- 23.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Clinical Infectious Diseases (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- hepatitis C, direct-acting antivirals, cost projections, daclatasvir, sofosbuvir, simeprevir, faldaprevir, ribavirin, generic drug production, treatment access, low- and middle-income countries, drug pricing
- MeSH terms
- Sofosbuvir, Simeprevir, Aminoisobutyric Acids, Antiviral Agents, Carbamates, Developing Countries, Drug Industry, Drug Therapy, Combination, Health Services Accessibility, Hepatitis C, Heterocyclic Compounds, 3-Ring, Humans, Imidazoles, Leucine, Oligopeptides, Proline, Pyrrolidines, Quinolines, Ribavirin, Sulfonamides, Thiazoles, Uridine Monophosphate, Valine, Hepacivirus, Anti-HIV Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.